OMASS THERAPEUTICS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  -19.4%

  £49,297,355 → £39,750,816

• Net assets

  -42%

  £55,142,842 → £31,959,431

• Employees

  0%

  60 → 60

• Operating profit

  -0.2%

  -£28,923,679 → -£28,995,920

• Profit before tax

  -1.4%

  -£27,318,983 → -£27,698,415

• Wages

  -3.9%

  £5,881,318 → £5,653,388

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. OMASS THERAPEUTICS LIMITED 2018-11-21 → present
2. OMASS TECHNOLOGIES LIMITED 2016-02-26 → 2018-11-21

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Management is actively managing cash reserves and the business, and in close communication with the investors and directors. On this basis, the directors are of the opinion that it is appropriate to adopt the going concern basis in the preparation of the financial statements.”

Group structure

1. OMASS THERAPEUTICS LIMITED · parent
   1. OMass Therapeutics Inc. 100% · Cambridge, MA 02142 · Biotechnology research and development activities
   2. OMass Therapeutics Australia Pty Ltd 100% · Hawthorn East VIC 3123 · Biotechnology research and development activities

Significant events

• “In August 2025, OMass entered into an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease. The agreement included a £14.8 million ($20 million) upfront, non-dilutive payment, with the potential for future development, regulatory and commercial milestones.”
• “In July 2024, the Company called the second and final tranche of Series B funding totalling £34.2 million following achievement of the Series B Tranche 2 milestones, which will continue to grow the Company and advance the portfolio of projects towards the clinic until further financing is received.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

9

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.